FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the U.S. Food and Drug Administration (FDA) granting accelerated approval to Breyanzi (lisocabtagene maraleucel; liso-cel). This approval marks a pivotal moment for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior systemic therapies. […]
